Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) BTC-USD
67,900.32 +1,915.98 (+2.90%) CMC Crypto 200
1,374.11 +43.50 (+3.27%)
Eisai Co., Ltd. (ESALF)
| Previous close | 43.50 |
| Open | 39.30 |
| Bid | 37.20 x 21500 |
| Ask | 41.68 x 41800 |
| Day's range | 38.50 - 39.30 |
| 52-week range | 37.53 - 66.84 |
| Volume | |
| Avg. volume | 722 |
| Market cap | 11.782B |
| Beta (5Y monthly) | -0.04 |
| PE ratio (TTM) | 40.53 |
| EPS (TTM) | 0.95 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | 1.02 (2.56%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | 75.99 |
PR NewswireEISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT06462404. Study sites are also planned for Canada.
PR NewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L
PR NewswireEisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with
